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Edited by Felix WielandAbstract Grifolin is a natural biologically active substance iso-
lated from the fresh fruiting bodies of the mushroom Albatrellus
conﬂuens. Here, for the ﬁrst time, we describe a novel activity of
grifolin, namely its ability to inhibit the growth of tumor cells by
the induction of apoptosis. Grifolin strongly inhibited the growth
of tumor cell lines: CNE1, HeLa, MCF7, SW480, K562, Raji
and B95-8. Analysis of acridine orange (AO)/ethidium bromide
(EB) staining and ﬂow cytometry showed that grifolin possessed
apoptosis induction activity to CNE1, HeLa, MCF7 and
SW480. Furthermore, the cytochrome c release from mitochon-
dria was detected by confocal microscopy in CNE1 cells after a
12 h treatment with grifolin. The increase of caspase-8, 9, 3
activities revealed that caspase was a key mediator of the apop-
totic pathway induced by grifolin, and the underexpression of
Bcl-2 and up-regulation of Bax resulted in the increase of Bax:
Bcl-2 ratio, suggesting that Bcl-2 family involved in the control
of apoptosis. Owing to the combination of the signiﬁcant antitu-
mor activity by inducing apoptosis and natural abundance of the
compound, grifolin holds the promise of being an interesting
antitumor agent that deserves further laboratory and in vivo
exploration.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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About 14 000 species of mushrooms are now known in the
world. They comprise a vast and yet largely untapped source
of powerful new pharmaceutical products. In particular, some
biologically active substances isolated from mushrooms inAbbreviations: IC50, 50% inhibitory concentration; DMSO, dimethyl
sulfoxide; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium
bromide; PBS, phosphate-buﬀered saline; AO, acridine orange; EB,
ethidium bromide; PI, propidium iodide; IETD-pNA, Ile–Glu–Thr–
Asp conjugated to p-nitroanilide; LEHD-pNA, Leu–Glu–His–Asp
conjugated to p-nitroanilide; DEVD-pNA, Asp–Glu–Val–Asp conju-
gated to p-nitroanilide
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doi:10.1016/j.febslet.2005.05.013fruit bodies, cultured mycelium, and culture broth exhibit
promising activity against tumors in vivo and in vitro. Some
have been employed clinically as antitumor drugs. For exam-
ple, PSK (Krestin) extracted from Coriolus versicolor has been
developed for anticancer therapy. It is taken orally for gastric
and other cancers. Irofulven derived from a family of mush-
room toxins as illudins possesses signiﬁcant antitumor activity
[1].
Apoptosis is the process of programmed cell death through a
tightly controlled program that plays important roles in many
normal processes, ranging from fetal development to adult tis-
sue homeostasis [2]. A tumor is a disease state characterized by
uncontrolled proliferation and a loss of apoptosis. Compounds
that block or suppress the proliferation of tumor cells by
inducing apoptosis are considered to have potential as antitu-
mor agents [3]. As a very valuable source for novel chemother-
apeutic reagents, active substances isolated from the
mushroom show eﬀective antitumor activities with wide range
of mechanisms. Some have been identiﬁed which induced
apoptosis in the tumor cells. For example, lectin isolated from
the edible mushroom Boletopsis leucomelas exerts the antitu-
mor eﬀects via apoptosis induction [4].
Grifolin is a natural biologically active substance isolated
from the fresh fruiting bodies of the mushroom Albatrellus
conﬂuens [5], which has shown various pharmacological and
microbiological eﬀects. In 1950, grifolin was deﬁned as an
antibiotic [6]. Research has shown that grifolin added to
the high cholesterol diet could signiﬁcantly lower plasma cho-
lesterol levels with limited or no toxicity [7]. Additionally,
grifolin possesses antioxidative activity [8] and signiﬁcantly
inhibit histamine release from rat peritoneal mast cells [9].
Until now, it has never been shown that grifolin possessed
antitumor activity whether in vivo or in vitro. Here, for the
ﬁrst time, we have discovered that grifolin inhibited the
growth of some cancer cell lines and induced apoptosis. In
our research, grifolin-triggered apoptosis was accompanied
by the cytochrome c release from mitochondria and the in-
crease of caspase-8, 9, 3 activities in nasopharyngeal carci-
noma cell line CNE1. Meanwhile, the ratio between of Bax
and Bcl-2, two proteins involved into the control of apoptosis
in CNE1 cells, markedly increased as result of grifolin treat-
ment. These results are signiﬁcant in that they provide a
mechanistic framework for further exploring the use of grifo-
lin as a novel antitumor agent.blished by Elsevier B.V. All rights reserved.
Fig. 1. Grifolin reduces the viability of CNE1 (A) at indicated time
and concentrations, and MCF7, HeLa, SW480, B95-8, K562 and Raji
(B), and NHBE and NIH/3T3 (C) at indicated concentrations. Cells
were treated with the grifolin, and then cell viability was measured by
MTT assay. In each treatment group, cells treated with medium were
the control and their viability was set as 100%. Values are expressed as
means ± S.D. of four experiments (n = 4).
Table 1
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2.1. Cell lines and culture
The following cell lines were used: human breast cancer cell line
MCF7 (ATCC HTB-22), human colon cancer cell line SW480 (ATCC
CCL-228), human cervical cancer cell line HeLa (ATCC CCL-2), mar-
moset B lymphoblastoid cell line B95-8, human chronic myelogenous
leukemia cell line K562 (ATCC CCL-243), human Burkitts Lym-
phoma cell line Raji (ATCC CCL-86), human nasopharyngeal carci-
noma cell line CNE1, normal human bronchial epithelial cell line
NHBE (Clonetics CC-2541), and mouse ﬁbroblast cell line NIH/3T3
(ATCC CRL-1658). MCF7, SW480, HeLa, B95-8, K562, Raji and
CNE1 were grown in RPMI 1640 supplemented with 10% heat-inacti-
vated fetal bovine serum, 1% glutamine, and 1% antibiotics. NHBE
were maintained in culture media as suggested by the Clonetics.
NIH 3T3 were grown in DMEM supplemented with 10% heat-inacti-
vated fetal bovine serum. All cell lines were cultured at 37 C in a
humidiﬁed incubator containing 5% CO2.
2.2. Chemicals
Grifolin (2-trans, trans-farnesyl-5-methylresorcinol) was provided by
Kunming Institute of Botany, the Chinese Academy of Sciences (pur-
ity > 99%, HPLC analysis) [5]. Dimethyl sulfoxide (DMSO, Sigma)
was used to dissolve grifolin. Benzyloxy carbonyl–Val–Ala–Asp–ﬂuo-
romethylketone (Z-VAD-fmk) was purchased from Promega (Madi-
son, Wisconsin, USA).
2.3. Cell viability assay (MTT)
Cell viability was determined by a colorimetric 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, as previously
described [10]. Brieﬂy, 1 day after exponentially growing cells were
seeded at 2 · 103 cells/well in a 96-well plate, the culture medium
was changed to the experimental medium supplemented with grifolin
at indicated concentrations. The ﬁnal concentration of DMSO in the
culture medium was found to have no antiproliferative eﬀect on either
cell line. Following culture with grifolin for 24, 48 and 72 h, MTT (Sig-
ma) was added, and the plate samples were read at 570 nm on a scan-
ning multiwell spectrophotometer. The 50% inhibitory concentration
(IC50) of grifolin on cells was calculated by MTT assay.
2.4. Fluorescence morphological examination
Apoptotic morphology was studied by staining the cells with a com-
bination of the ﬂuorescent DNA-binding dyes acridine orange (AO)
and ethidium bromide (EB). Cells were harvested and washed three
times with phosphate-buﬀered saline (PBS) after being incubated with
diﬀerent concentrations of grifolin for 48 h, and were then stained with
100 lg/ml AO and EB (AO/EB; Sigma) for 2 min. Then the color and
structure [11] of the diﬀerent cell types were observed under a ﬂuores-
cence microscope (Olympus).
2.5. Flow cytometry assay
Flow cytometry was used to quantitatively detect the apoptotic rate.
Cells (1 · 106) were plated into 10-cm tissue culture dishes 1 day before
the treatment, and were then treated with grifolin at various concentra-
tions. Forty-eight hours after the treatment, ﬂoating and attached cells
were harvested, washed with PBS, ﬁxed in 70% ethanol overnight at
4 C, and stained with propidium iodide (PI; Sigma) 50 mg/ml. The
sub-G1 peak (DNA content less than 2 N) was measured with FAC-
Scan Flow Cytometry (Becton Dickinson) and analyzed by Cell Quest
software.
2.6. Caspase activity assay
Caspase activation was measured using a caspase colorimetric assay
kit as described by the manufacturer (BioVision). Brieﬂy after the cell
treatment with 40 lM grifolin for the indicated periods of time, cells
were harvested, pelleted and frozen on dry ice. Cell lysis buﬀer was
added to the cell pellets, and protein concentration was determined
by a micro BCA kit (Pierce). Then 100 lg protein was diluted in
50 ll cell lysis buﬀer for each assay, and 50 ll of 2 · reaction buﬀer
supplemented with 10 mM DTT were then added to each tube incu-
bated at 4 C. The substrates of Ile–Glu–Thr–Asp conjugated to
p-nitroanilide (IETD-pNA), Leu–Glu–His–Asp conjugated to p-nitro-
anilide (LEHD-pNA), and Asp–Glu–Val–Asp conjugated to p-nitro-anilide (DEVD-pNA) were added into the tubes, respectively.
Formations of p-nitroanilide were measured by ELISA Micro-plate
Reader (Bio-tek) at 405 nm after the samples were incubated for
1.5 h at 37 C. Caspase-8-, caspase-9-, and caspase-3-like enzymatic
activities were assessed in parallel.
2.7. Western blot analysis
After cells were treated for 48 h with grifolin, cells were washed with
cold PBS and subjected to lysis in lysis buﬀer [50 mM/L Tris Æ Cl,
1 mM/L EDTA, 20 g/L SDS, 5 mM/L dithiothreitol, 10 mM/L
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50 lg protein) and rainbow molecular weight markers (Amersham
Pharmacia Biotech, Amersham, United Kingdom) were separated byFig. 2. Grifolin induces apoptotic morphological changes on CNE1 cells. A
CNE1 cells were harvested, washed with PBS, and stained with AO/EB (100
Green live cells show normal morphology in control (A); green early apopt
30 lM (B) or 40 lM (C) grifolin treatment. Orange later apoptotic cells sho
50 lM grifolin treatment (D). (·400).
Fig. 3. Grifolin increases the apoptotic rates of cells. After CNE1, MCF7, He
indicated concentrations, cells were harvested and washed with PBS, ﬁxed w
DNA content was measured by ﬂow cytometry. The apoptotic population wa
content. Similar results were obtained in at least three other independent ex12% SDS–PAGE and then electrotransferred to the nitrocellulose
membrane. Membranes were blocked with buﬀer containing 5% fat-
free milk in PBS with 0.05% Tween 20 for 2 h, and incubated withfter being treated with indicated concentrations of grifolin for 48 h.
lg/ml). Cell morphology was observed under ﬂuorescence microscopy.
otic cells show nuclear margination and chromatin condensation with
wed fragmented chromatin and apoptotic bodies after 40 lM (C) or
La and SW480 were grown in medium alone or treated with grifolin in
ith ice-cold 70% ethanol, stained with PI, and treated with RNase A.
s measured as the percentage of total cell populations with <G1 DNA
periments.
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nal antibody (Santa Cruz Biotech) overnight at 4 C. After a second
wash with PBS with 0.05% Tween 20, the membranes were incubated
with peroxidase-conjugated secondary antibodies (Santa Cruz Biotech)
and developed with a chemiluninescence detection kit (ECL; Pierce). a-
Tubulin was used as a loading control.
2.8. Confocal laser microscopy
Cells were untreated or treated with grifolin for 12 h. After ﬁxation
with 2% formaldehyde, cells were permeabilized for 10 min in 0.5%
Triton X-100 in PBS. They were then incubated for 10 min in 100 mM
glycine in PBS, and DNA was stained by 1 lg/ml DAPI (Vysis) in PBS
and washed twice for 5 min with PBS. Incubation with the mouse anti-
cytochrome c antibody (BioVision) was performed for 1–2 h at room
temperature after the dilution in PBS and visualized with goat anti-rat
IgG Cy3 antibody (Amersham Biosciences). Images were obtained by
confocal laser scanning microscopy (LSM 410; Zeiss, Jena, Germany).3. Results
3.1. Growth inhibitory eﬀect of grifolin on tumor cell lines
In a primary screening test, we found that grifolin was able
to decrease nasopharyngeal carcinoma cell line CNE1 viability
in a dose- and time-dependent manner (Fig. 1A), whereas mostFig. 4. Activation of caspase-8, caspase-9, caspase-3 by grifolin. CNE1
cells were incubated with grifolin (40 lM) for indicated time before the
caspase-8 substrate IETD-pNA, or caspase-9 substrate LEHD-pNA,
or caspase-3 substrate DEVD-pNA (50 mM) was added. Assay
mixtures were incubated for 1.5 h at 37 C. Activation of caspase-8
(A), caspase-9 (B), caspase-3 (C) was measured by ELISA Micro-plate
Reader (Bio-tek) at 405 nm. Results are presented as means ± S.D.
(three independent experiments).of the chemicals isolated from higher fungi had no eﬀect on it
(Data not shown). Thus, the cell killing eﬀects of this com-
pound were further evaluated in vitro in six tumor cell lines
of diﬀerent origins. Cells were treated with various concentra-
tions of grifolin for 72 h. The survival rates of cells were de-
creased in a dose-dependent manner (Fig. 1B). The
concentrations required to inhibit cell growth by 50% (IC50)
for CNE1, MCF7, HeLa, SW480, K562, Raji, and B95-8 were
24, 30, 33, 27, 18, 27 and 24 lM, respectively (Table 1). In
addition, we examined the eﬀect of grifolin on the survival rate
of normal, non-tumor cell lines, such as NHBE (normal hu-
man bronchial epithelial cell line) and NIH/3T3 (mouse ﬁbro-
blast cell line) (Fig. 1C). As compared with the panel of tumor
cell lines analyzed, we found grifolin had some selective antitu-
mor eﬀect. The comparison of the respective IC50 (Table 1)
showed that normal cells were less sensitive to grifolin in vitro.
3.2. Induction of apoptosis by grifolin
To determine whether the growth inhibitory activity of grif-
olin was related to the induction of apoptosis, morphological
assay of cell death was investigated using the AO/EB staining
for ﬂuorescence microscopy. After CNE1 cells were exposed to
various concentrations of grifolin for 48 h, diﬀerent morpho-
logical features were analyzed. Uniformly green live cells with
normal morphology were seen in the control group (Fig. 2A),
whereas green early apoptotic cells with nuclear margination
and chromatin condensation occurred in the experimental
group with 30 and 40 lM grifolin (Fig. 2B and C), orange later
apoptotic cells with fragmented chromatin and apoptotic
bodies were seen when grifolin was at the concentration of
40 and 50 lM (Fig. 2C and D). The results suggested that grif-
olin was able to induce marked apoptotic morphology in
CNE1 cells. Meanwhile, apoptotic morphology was also found
in MCF7, HeLa, SW480, Raji, K562 and B95-8 (Data not
shown). Further, we quantiﬁed the apoptotic cells after grifolin
treatment by ﬂow cytometry analysis using PI staining. By this
technique, apoptotic nuclei are identiﬁed in the subdiploid re-Fig. 5. Inhibition of grifolin-induced apoptosis by the caspase
inhibitor Z-VAD-fmk. CNE1 cells were treated with either 20 lM Z-
VAD-fmk alone or 20 lM Z-VAD-FMK in combination with 40 lM
for 48 h and analyzed for apoptosis by ﬂow cytometry. Results are
presented as means ± S.D. (three independent experiments).
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ment at diﬀerent concentrations of grifolin resulted in a dra-
matic increase of apoptosis. Apoptotic rate in CNE1, MCF7,
HeLa and SW480 cells increased from 1.84% to 68.3%,
1.89% to 67.8%, 1.96% to 70.7% and 0.57% to 60.2%, respec-
tively, in a dose-dependent manner (Fig. 3).
3.3. Activation of caspase induced by grifolin
The caspase family is at the heart of apoptotic machinery,
where these enzymes play key roles in the execution of apopto-
sis [12]. Morphological assay of apoptosis led us to hypothe-
size that grifolin might activate the caspase-dependent cell
death pathway. Thus, the activation of caspase induced by
grifolin was further evaluated in CNE1 cells. To identify
whether caspase was involved in the mechanism, we measured
the catalytic activity of caspase-8, caspase-9 and caspase-3.
The result showed that caspase-3 and caspase-8 activities were
rapidly elevated and peaked at 6 h of grifolin treatment (Fig.
4A and C), whereas caspase-9 activity peaked at 12 h (Fig.
4B). However, caspase-9 activity levels were lower than those
of caspase-8. In addition, we found that caspase-3 activity re-
mained at a high level at 12 h (Fig. 4C), which may be associ-
ated with the increased level of caspase-9 activity.
To further demonstrate the involvement of caspase activa-
tion in the apoptotic eﬀect, we analyzed whether the pan-
caspase inhibitor Z-VAD-fmk prevented apoptosis. When
CNE1 cells were incubated with 40 lM grifolin in the presence
of the 20 lM caspase inhibitor Z-VAD-fmk, we observed thatFig. 6. Eﬀect of grifolin on cytochrome c release. Microscopic analysis of c
medium (A) and cells treated for 12 h with 40 lM grifolin (B) were ﬁxed and
with confocal laser scanning microscopy.the apoptotic response was reversed by more than 80% (Fig.
5). These ﬁndings allow us to conclude the involvement of cas-
pase-dependent pathway(s) in grifolin-induced apoptotic death
of CNE1 cells.
3.4. Release of cytochrome C induced by grifolin
Cytochrome c is localized in the intermembrane space and
loosely attached to the surface of the inner mitochondrial mem-
brane. In response to a variety of apoptosis-inducing agents,
cytochrome c is released from mitochondria to the cytosol
[13]. To examine this step in the apoptotic cell death pathway
initiated by grifolin, the subcellular localization of cytochrome
cwas determined by confocal laser microscopy after immunola-
beling cytochrome c in CNE1 cells. After cells were treated for
12 h at 40 lM, the staining pattern became diﬀuse in most cells
(Fig. 6B), consistent with a translocation of cytochrome c into
the cytosol, whereas cytochrome c displayed a dotted pattern in
untreated cells, consistent with its location within the mito-
chondria (Fig. 6A). Meanwhile, the condensation and margin-
ation of the chromatin of the nucleus was also observed by
staining DNA with DAPI (Fig. 5) in these cells with diﬀuse
cytochrome c staining. Therefore, we conclude that cytochrome
c release is part of the apoptosis pathway induced by grifolin.
3.5. Up-regulation of Bax and down-regulation of Bcl-2 by
grifolin
Although the caspase proteolytic cascade is a central point in
apoptotic response, its activity was tightly regulated by aytochrome c and DNA-stained CNE1 cells. CNE1 cells with control
labeled for cytochrome c (red) and DNA (blue). Images were obtained
Fig. 7. Eﬀect of grifolin on the expression of Bcl-2 and Bax in CNE1
cells. Exponentially growing CNE1 cells were treated with indicated
concentrations of grifolin for 48 h, cell lysates were prepared and
protein level of Bcl-2 and Bax was determined by Western blotting
analysis. The expression of Bcl-2 and Bax after grifolin induction at
indicated concentrations (A). a-Tubulin was used for normalization
and veriﬁcation of protein loading. Quantitative Bcl-2 and Bax
expression after normalization to a-tubulin (n = 3 at each concentra-
tion point) (B). The Bax:Bcl-2 ratio corresponding to indicated
concentrations of grifolin (C). Values are means ± S.D.
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ing anti-apoptotic members (such as Bcl-2) and pro-apoptotic
members (such as Bax), play a pivotal role [14]. To further ana-
lyze the possible mechanism underlying the grifolin-induced
apoptosis, we tested the expression of Bcl-2 and Bax in CNE1
cells after grifolin treatment. After being normalized to a-tubu-
lin, the expression of Bcl-2 was decreased signiﬁcantly, while
Bax protein level was increased markedly in a dose-dependent
manner (Fig. 7A and B). The ratio of Bax: Bcl-2 was dramati-
cally increased in a dose-dependent manner (Fig. 7C).4. Discussion
The ability to induce tumor cell apoptosis is an important
property of a candidate anticancer drug, which discriminates
between anticancer drugs and toxic compounds [3]. Here, weshowed grifolin isolated from the mushroom A. conﬂuens
was able to inhibit the growth of 7 tumor cell lines in a
dose-dependent manner. Further, we evaluated that the
growth inhibitory activity of grifolin was associated with the
induction of apoptosis in CNE1 cells. Treatment of CNE1 cells
with grifolin resulted in a dose-dependent generation of apop-
tosis-speciﬁc morphological changes and apoptotic rates. In
addition, we found grifolin was also able to induce apoptosis
in other cancer cell lines, including MCF7, HeLa, SW480,
Raji, K562 and B95-8.
Caspases are a ubiquitous family of cysteine proteases that
include both upstream (initiator) and downstream (eﬀector)
caspase [15]. The initiator caspases, typically caspase-8 and
caspase-9, are activated by two alternative pathways. The ﬁrst
involves cell death receptor-mediated apoptosis through cas-
pase-8 [16]. It is characterized by binding cell death ligands
and cell death receptors, and subsequently activates caspase-
8 and caspase-3 [17,18]. The second involves mitochondria-
mediated apoptosis through caspase-9. The key element in
the pathway is the eﬄux of the cytochrome c from mitochon-
dria to cytosol. Once cytochrome c is in the cytosol, cyto-
chrome c together with Apaf-1 activates caspase-9, and the
latter then activates caspase-3 [19]. In both pathways the initi-
ator caspase cleaves and activates downstream, eﬀector casp-
ases, such as caspase-3 [20]. This caspase cascade ultimately
leads to proteolytic cleavage and induces the broad range of
the morphological changes of apoptosis. Our results indicate
that caspase-8, caspase-9 and caspase-3 activities were rapidly
elevated after the grifolin treatment, and the kinetic activation
of caspase-3 was associated with the activation of caspase-8
and caspase-9. An important role for caspases in grifolin-
induced apoptosis was also suggested by the observation that
Z-VAD-fmk reversed the apoptotic eﬀect exerted by grifolin
in CNE1 cells. Because Z-VAD-fmk is a general inhibitor of
caspases [21], this ﬁnding demonstrates the involvement of cas-
pase-dependent mechanisms in grifolin-mediated apoptosis of
CNE1 cells. But, we also found grifolin was able to induce
apoptosis in caspase-3-deﬁcient MCF-7 cells by ﬂow cytometry
analysis. It deserved further investigation on about whether
grifolin may induce other death pathway. On the other hand,
we found that grifolin was able to induce cytochrome c release
from the mitochondria in CNE1 cells by confocal laser micros-
copy after immunolabeling cytochrome c. Therefore, our study
indicated that mitochondrial pathway and death receptor sig-
naling pathway were both involved in apoptosis induced by
grifolin in CNE1 cells.
Apoptosis is a tightly regulated process, which involves
changes in the expression of distinct genes [22]. Bcl-2 family
proteins that consist of anti-apoptotic and pro-apoptotic mem-
bers are important regulators of apoptosis [23]. Overexpression
of pro-apoptotic Bax induces the release of cytochrome c from
mitochondria. Released cytochrome c contributes to apoptosis
through binding Apaf-1 and caspase-9, whereas, anti-apopto-
tic Bcl-2 binds to Bax and can form heterodimers, which inhi-
bit Bax activity and block apoptosis in cells. The ratio of Bcl-2
to Bax protein has been reported to be associated with apop-
tosis [23–26], and used as a predictive marker for therapeutic
response to radiotherapy [27]. Our data clearly demonstrated
that grifolin treatment to CNE1 cells resulted in a dose-depen-
dent increase in the level of Bax with a concomitant decrease in
Bcl-2 levels and increase in Bax/Bcl-2 ration. Studies have
shown P53 is very important regulatory protein targeting
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Wild-type p53 can down-regulate the expression of Bcl-2 and
up-regulate that of Bax, altering the balance of the couple
genes in favor of apoptosis [28]. Meanwhile, several studies
have demonstrated that Stat3 can up-regulate the expression
of Bcl-2 [29]. EGCG can decrease the level of the Bcl-2 protein
by inhibiting Stat3 [30]. However, the precise mechanism by
which grifolin decreased Bcl-2 and increased Bax expression
in CNE1 cell remains to be determined.
In conclusion, grifolin signiﬁcantly inhibited the growth of
some cancer cell lines in vitro. The cancer-suppressing mecha-
nism involved the induction of apoptosis. We further proved
that apoptosis of CNE1 cells was induced by the activation
of caspase-8, caspase-9, and caspase-3, release of cytochrome
c from mitochondria, decrease of the Bcl-2 level, and increase
of the Bax level. Determining the detailed mechanism of grifo-
lin action and exploring its pharmacokinetics may lead to the
development of a novel antitumor drug.
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